AZD-6918

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2R)-2-[[4-[(3-chloro-4-fluorophenyl)amino]quinazolin-6-yl]oxy]butanamide | image = | width = 250 | CAS_number = 123456-78-9 | PubChem = 12345678 | ChemSpiderID = 12345678 | UNII = 123456789A | KEGG = D12345 | ChEMBL = 1234567 | C=18 | H=16 | Cl=1 | F=1 | N=3 | O=2 | molecular_weight = 361.79 g/mol }}

AZD-6918 is an investigational drug developed for the treatment of certain types of cancer. It is a small molecule inhibitor that targets specific pathways involved in tumor growth and proliferation. AZD-6918 is primarily being studied for its potential efficacy in non-small cell lung cancer (NSCLC) and other solid tumors.

Mechanism of Action

AZD-6918 functions as a tyrosine kinase inhibitor (TKI). It specifically inhibits the activity of the epidermal growth factor receptor (EGFR), which is often overexpressed or mutated in various cancers. By blocking EGFR signaling, AZD-6918 aims to reduce cancer cell proliferation and induce apoptosis.

Clinical Development

AZD-6918 is currently in the early stages of clinical development. Preclinical studies have shown promising results in terms of its ability to inhibit tumor growth in animal models. Phase I clinical trials are underway to evaluate the safety, tolerability, and pharmacokinetics of AZD-6918 in humans.

Potential Benefits

The development of AZD-6918 is part of a broader effort to create targeted cancer therapies that are more effective and have fewer side effects than traditional chemotherapy. By specifically targeting cancer cells with overactive EGFR signaling, AZD-6918 may offer a more personalized treatment option for patients with EGFR-driven tumors.

Challenges and Considerations

While AZD-6918 shows potential, there are several challenges in its development. Resistance to EGFR inhibitors is a known issue, and researchers are investigating combination therapies to overcome this. Additionally, the identification of biomarkers to predict patient response to AZD-6918 is an ongoing area of research.

Also see

• Epidermal growth factor receptor
• Tyrosine kinase inhibitor
• Non-small cell lung cancer
• Targeted cancer therapy

External links

• National Cancer Institute: Targeted Cancer Therapies
• ClinicalTrials.gov